Table 1 Baseline clinical parameters
Absorb (n = 10) | Synergy (n = 10) | p | |
|---|---|---|---|
N (%) | N (%) | ||
Age (years) | 56.5 ± 13.6a | 61.4 ± 9.0 | 0.350 |
Male | 9 (90.0) | 7 (70.0) | 0.582 |
Treatment for hypertension | 3 (30.0) | 3 (30.0) | 1.000 |
Treatment for hypercholesterolemia | 2 (20.0) | 0 (0.0) | 0.474 |
Diabetes mellitus | 1 (10.0) | 0 (0.0) | 1.000 |
Current smoking | 5 (50.0) | 4 (40.0) | 1.000 |
MDRD clearance < 60 ml/min/1.73 m2 | 1 (10.0) | 1 (10.0) | 1.000 |
Fasting plasma glucose ≥ 7 mmol/l | 3 (30.0) | 8 (80.0) | 0.070 |
LVEF (%) | 52.5 ± 7.9 | 52.9 ± 10.3 | 0.923 |
LAD significant lesion (> 50%) | 9 (90.0) | 7 (70.0) | 0.582 |
Cx significant lesion (> 50%) | 5 (50.0) | 1 (10.0) | 0.141 |
RCA significant lesion (> 50%) | 5 (50.0) | 8 (80.0) | 0.350 |
> 1-vessel disease | 8 (80.0) | 6 (60.0) | 0.628 |